Astellas Pharma and Pfizer have announced unprecedented results from the pivotal Phase 3 EV-303 clinical trial (KEYNOTE-905), with the combination of PADCEV (enfortumab vedotin) and MSD's KEYTRUDA (pembrolizumab) delivering significant survival benefits for cisplatin-ineligible patients with muscle-invasive bladder cancer. …
New combination therapy sets landmark survival benchmark in bladder cancer treatment
October 19, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
Cartherics and Catalent deepen partnership to accelerate next generation cell therapies
April 10, 2026 - - Australian Biotech -
Lower official co-payment but patients paying for more unsubsidised medicines
April 10, 2026 - - Latest News -
The 'Dispatched' Week in Review Podcast - 10 April
April 10, 2026 - - Podcast -
Is there any example of another review or inquiry taking this long?
April 10, 2026 - - Latest News -
Rewriting the rules of PBS negotiations to deliver a patient-first reset
April 10, 2026 - - Latest News -
A decade of readiness as AVITA medical expands burn response capability
April 9, 2026 - - Australian Biotech -
Moderna names Carolyn Tucek-Szabo to lead Australia and New Zealand operations
April 9, 2026 - - Latest News